IP Library Granted Patent US 8,563,519
Granted Patent B2
US 8,563,519 · App. 11/075,645 · Granted Oct 22, 2013

Methods of activating or inhibiting G protein coupled receptors (GPCRs)

Inventors: Athan Kuliopulos (Winchester, MA); Lidija Covic (Boston, MA)
Assignee: Tufts Medical Center, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,519
App. No.
11/075,645
Granted
Oct 22, 2013
Kind
B2
Abstract

The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.

Claims (15)

1. A method of modulating signaling associated with a chemokine receptor, said method comprising contacting a cell that expresses said chemokine receptor with a compound, wherein the compound comprises:

(i) a first domain comprising the third intracellular loop (i3 loop) of said chemokine receptor, or a fragment thereof, wherein said fragment comprises at least 5 contiguous amino acid residues of said i3 loop; and

(ii) a second domain, attached to the first domain, wherein the second domain comprises a cell-penetrating, membrane-tethering hydrophobic moiety;

wherein said compound binds to its cognate chemokine receptor.

2. The method of claim 1 , wherein said i3 loop fragment comprises at least 7 contiguous amino acid residues of the third intracellular loop.

3. The method of claim 1 , wherein said second domain comprises a lipid moiety.

4. The method of claim 1 , wherein said second domain comprises a hydrophobic moiety that is selected from the group consisting of: capryloyl (C 8 ); nonanoyl (C 9 ); capryl (C 10 ); undecanoyl (C 11 ); lauroyl (C 12 ); tridecanoyl (C 13 ); myristoyl (C 14 ); pentadecanoyl (C 15 ); palmitoyl (C 16 ); phytanoyl ((CH 3 ) 4 ); heptadecanoyl (C 17 ); stearoyl (C 18 ); nonadecanoyl (C 19 ); arachidoyl (C 20 ); heneicosanoyl (C 21 ); behenoyl (C 22 ); trucisanoyl (C 23 ); and lignoceroyl (C 24 ).

5. The method of claim 1 , wherein said second domain comprises a palmitoyl (C 16 ) moiety.

6. The method of claim 1 , wherein said second domain comprises a myristoyl (C 14 ) moiety.

7. The method of claim 1 , wherein said second domain comprises a pentadecanoyl (C 15 ) moiety.

8. The method of claim 1 , wherein said second domain comprises a steroid.

9. The method of claim 1 , wherein said second domain comprises a hydrophobic moiety that is selected from the group consisting of: a phospholipid, a steroid, a sphingosine, a ceramide, an octylglycine, a 2-cyclohexylalanine, and a benzolylphenylalanine.

10. The method of claim 1 , wherein said compound further comprises a third domain, said third domain comprising a cell-penetrating, membrane tethering hydrophobic moiety attached to said first domain.

11. The method of claim 1 , wherein the chemokine receptor is CXCR4.

12. The method of claim 1 , wherein the chemokine receptor is CCR5.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2010
From: KULIOPULOS, ATHAN; COVIC, LIDIJA
To: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.
Reel/Frame 024134/0128 →
CHANGE OF NAME Recorded Mar 25, 2010
From: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.
To: TUFTS MEDICAL CENTER, INC.
Reel/Frame 024134/0223 →
CONFIRMATORY LICENSE Recorded Jul 17, 2008
From: NEW ENGLAND MEDICAL CENTER HOSPITALS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021249/0730 →
Continuity (3)
Division 09841091 · Apr 23, 2001
Provisional Application 60198993 · Apr 21, 2000
Related Publication 20060166274A1 · Jul 27, 2006